Unlocking the full potential of artificial intelligence requires these stakeholders to ensure their data are accessible and secure.
Inger Ødum Nielsen, Vanessa de Langsdorff, and John April
Advertisement
Articles by Inger Ødum Nielsen, Vanessa de Langsdorff, and John April
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Data Quality as Foundational to Trial Modernization, CRAs Evolving to Strategic Site Partners, and 2026 Emerging Pharma Leaders Announced
2
Closing the Dead Time Gap in Clinical Data: Q&A with Raviv Pryluk, PhaseV
3
ACT Brief: Training Completion Versus Execution Readiness, AI Monitoring Agent Financial Value at Scale, and FDA Warning Letters and AI Oversight Gaps
4
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
5